Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,032
datasets available to search
ShareScore release 0.9.0
Dataset results
2,032 results for “metastases”
Expression data from fine-needle aspiration biopsies of breast cancer metastases from different anatomical sites
GEO Series GSE56493. Homo sapiens. 120 samples. Type: Expression profiling by array.
Effect of Omomyc on lymph node metastases from melanomas [SkMel147]
GEO Series GSE227843. Homo sapiens. 8 samples. Type: Expression profiling by array.
Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes
GEO Series GSE85258. Homo sapiens. 31 samples. Type: Expression profiling by array.
MicroRNA-196b-5p is a prognostic factor in colorectal cancer patients and influences cancer cell migration and metastases formation through regulation of HOXB7 and GalNT5
GEO Series GSE86575. Homo sapiens. 6 samples. Type: Expression profiling by array.
Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells
GEO Series GSE67088. Homo sapiens. 6 samples. Type: Expression profiling by array.
Isolated limb perfusion and immunotherapy in the treatment of in-transit melanoma metastases
<p><strong><span>Background:</span></strong><span> Isolated limb hyperthermic-antiblastic perfusion (ILP) was the most effective local treatment for advanced in-transit melanoma, but the advent of modern effective immunotherapy (IT) such as immune checkpoint inhibitors has changed the treatment landscape. <strong>Methods:</strong> This study evaluated the role of the association between ILP and IT in the treatment of locally advanced unresectable melanoma, in particularly in relation to modern systemic therapies. We analyzed 187 consecutive patients who were treated with ILP (melphalan or melphalan associated with TNF-alpha) for advanced melanoma at the Veneto Institute of Oncology of Padua (Italy) and the Padua University Hospital (Italy) between June 1989 and September 2021. Overall survival (OS), disease specific survival (DSS), local disease-free survival (local DFS) and distant disease-free survival (distant DFS) were evaluated. Local toxicity was classified according to the Wieberdink scale and surgical complications according to the Clavien-Dindo classification. Response to locoregional therapy was evaluated during follow-up according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumor). <strong>Results</strong>: 99 patients were treated with ILP and 88 with IT+ILP. Overall response rate was 67% in both groups. At 36 months, OS was 43% in ILP group and 61% in ILP+IT group (p=0.02); DSS was 43% in ILP group and 64% in ILP+IT group (p=0.02); local DFS was 37% in ILP group and 53% in ILP+IT group (p=0.04); distant DFS was 33% in ILP group and 35% in ILP+IT group (p=0.40). Adjusting for age and lymph node involvement, receiving ILP+IT was associated with improved OS (p=0.01) and DSS (p=0.007) but not local DFS (p=0.13) and distant DFS (p=0.21). <strong>Conclusions:</strong> Our findings confirm the synergy between ILP and IT. ILP remains a valuable loco-regional treatment option in the era of effective systemic treatments. Further studies are needed to establish the optimal combination of loco-regional and systemic treatments, and address the best timing of this combination to obtain the highest local response rate</span>.</p>
Dataset related to article "The pattern of failure after Stereotactic Radiation Therapy (SRT) for oligo-metastases: predictive factors for poly-progression "
<p>This record contains raw data related to article "The pattern of failure after Stereotactic Radiation Therapy (SRT) for oligo-metastases: predictive factors for poly-progression"</p><p>Abstract</p><p><strong>Purpose: </strong>Patients with oligo-metastatic disease (OMD) can be safely treated with Stereotactic Radiation Therapy (SRT). Further disease progression is common in these patients. In most cases, patients relapse again with oligo-metastases, however some can experience a poly-progression after a local ablative treatment (LAT). The purpose of this study was to retrospectively identify factors associated with poly-progression in patients receiving SRT for OMD.</p><p><strong>Methods: </strong>Data from a monocentric database were retrospectively analyzed. Patients treated with SRT for OMD and who developed progression after LAT were selected. Patients were categorized as oligo- or poly-progressive according to the number of new/progressing metastases (≤ or > 5). Herein, we analyzed data about patients' characteristics, oligo-metastatic presentation and radiation treatment characteristics to evaluate their relationship with progression type.</p><p><strong>Results: </strong>From 2013 to 2021, data on 700 patients progressing after LAT were analyzed. Among them, 227 patients (32.4%) experienced a poly-progression; the median time to poly-progression was 7.72 months (range 1-79.6). Five variables associated with poly-progression were found to be statistically significant in the univariate analysis: performance status (p < 0.001), site of the primary tumor (p = 0.016), ablative dose (p = 0.002), treated site (p = 0.002), single or double organ (p = 0.03). Of those, all but the number of involved organs retained their significant predictive value on the multivariate analysis.</p><p><strong>Conclusion: </strong>Our study identified four independent factors associated with poly-progression in patients with OMD receiving SRT. Our data may support comprehensive characterization of OMD, better understanding of factors associated with progression.</p>
Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases
ClinicalTrials.gov study NCT03732482. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases
ClinicalTrials.gov study NCT06483672. IPD Sharing: NO. Countries: 0. Publications: 0.
Adrenalectomy for Solitary Adrenal Gland Metastases
ClinicalTrials.gov study NCT01135238. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Diagnostic CT Palliative Radiotherapy: Feasibility Study of Treating Bone Metastases Without a CT Simulation
ClinicalTrials.gov study NCT06235034. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ElastoMRI Evaluation of Hepatic Metastases in Colorectal Cancer ( MetaIRM)
ClinicalTrials.gov study NCT06552117. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
ClinicalTrials.gov study NCT06504901. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Efficacy of a Herbal Formula for Bone Metastases
ClinicalTrials.gov study NCT06023420. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Merestinib on Bone Metastases in Subjects With Breast Cancer
ClinicalTrials.gov study NCT03292536. IPD Sharing: NO. Countries: 1. Publications: 0.
Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases (IMMETAOS)
ClinicalTrials.gov study NCT02876731. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases
ClinicalTrials.gov study NCT07199413. IPD Sharing: NO. Countries: 0. Publications: 0.
Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases
ClinicalTrials.gov study NCT01187290. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases.
ClinicalTrials.gov study NCT02331641. IPD Sharing: Not stated. Countries: 0. Publications: 0.
RELIEVE: Research on Effectiveness of Surgery and Radiotherapy on Relieving Spine Tumor Pain in Patients with Vertebral Metastases
ClinicalTrials.gov study NCT06746103. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.